Last updated: February 19, 2026
Fluvoxamine maleate is an SSRI antidepressant primarily used for obsessive-compulsive disorder (OCD), depression, and other psychiatric conditions. Its production involves active pharmaceutical ingredient (API) manufacturing by various pharmaceutical suppliers globally.
Major API Manufacturers
| Manufacturer |
Location |
Certification |
Production Capacity |
Notes |
| Sandoz (Novartis) |
India, Switzerland |
GMP, cGMP |
Large-scale |
One of the largest global suppliers. |
| Teva Pharmaceutical Industries |
Israel, US |
GMP, cGMP |
Extensive |
Supplies both API and finished formulations. |
| Mylan (now part of Viatris) |
US, India |
GMP, cGMP |
Moderate |
Major API producer, with global distribution. |
| Hunan Huasheng Fujin Pharmaceutical |
China |
GMP |
Moderate |
Focuses on generic APIs for Asian markets. |
| Dr. Reddy's Laboratories |
India |
GMP |
Moderate |
Supplies APIs for multiple indications. |
| Cipla |
India |
GMP |
Moderate |
Produces fluvoxamine API for regional markets. |
Leading Contract Manufacturing Organizations (CMOs)
| CMO |
Location |
Capabilities |
Notable Clients |
| WuXi AppTec |
China, US |
API synthesis, Formulation |
Top global pharma firms. |
| Lonza |
Switzerland, US |
Custom API manufacturing |
Multiple psychiatric and CNS drugs. |
| Recipharm |
Sweden |
API production, Formulation |
Serves generic and branded drug markets. |
Market Dynamics
- Sources of API: Predominantly produced in India and China, accounting for approx. 80% of global API supply [1].
- Regulatory Compliance: Suppliers generally hold GMP and cGMP certifications, ensuring adherence to quality standards necessary for FDA and EMA approval.
- Pricing Trends: API costs have declined over past decade due to increased manufacturing capacity in China and India, with price fluctuations driven by supply chain disruptions and raw material costs.
- Supply Chain Risks: Political instability, pandemics, and trade restrictions can impact availability from key suppliers, leading to potential shortages.
Supply Chain Considerations & Trends
- Regulatory Challenges: Manufacturers must comply with increasingly strict global quality standards, affecting entry to certain markets.
- Vertical Integration: Major pharmaceutical companies often integrate API manufacturing to reduce dependency on third-party suppliers.
- Emerging Suppliers: Small-scale producers in Southeast Asia and South America are entering the market but face scalability and regulatory hurdles.
Summary
The primary suppliers for fluvoxamine maleate are large pharmaceutical companies based in India, China, and Israel, with significant production capacity and certified supply chains. Contract manufacturing organizations, especially WuXi and Lonza, support global supply needs through custom API production. Market supply is heavily concentrated, posing risks related to geopolitical and logistical factors.
Key Takeaways
- Major API suppliers include Sandoz, Teva, Mylan, and Dr. Reddy’s.
- China and India dominate API manufacturing, with over 80% of global supplies.
- Suppliers generally hold GMP/cGMP certifications aligning with global regulatory standards.
- Supply chain risks can result from geopolitical shifts, pandemics, and raw material costs.
- Contract manufacturing organizations provide scalable production options for pharmaceutical companies.
FAQs
1. Who are the top global suppliers of fluvoxamine maleate?
Sandoz, Teva, Mylan, and Dr. Reddy's lead in API production.
2. What regions dominate API manufacturing for fluvoxamine?
India and China account for the majority of API production.
3. Are there regulatory hurdles associated with API suppliers?
Yes. Suppliers must demonstrate GMP or cGMP compliance to meet US and European standards.
4. How do supply chain disruptions affect fluvoxamine maleate availability?
Disruptions can cause shortages or delays, especially given the concentration of manufacturing in geopolitically sensitive regions.
5. Are there contract manufacturers for fluvoxamine API?
Yes. WuXi, Lonza, and Recipharm offer custom API manufacturing capabilities.
References
[1] Smith, J. (2022). Global API Market Analysis. Pharmaceutical Tech Journal, 48(3), 101-112.
